News | News By Subject | News by Disease News By Date | Search News

Hepatitis-C News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Johnson & Johnson (JNJ) Quits Multibillion-Dollar Hep C Drug Program, Partners' Stocks Fall     9/13/2017
AbbVie (ABBV) Wins FDA Approval for the First-Ever Drug to Treat All Forms of Hep C     8/7/2017
FDA Green Lights Gilead (GILD)'s Vosevi, With a Black Box Warning Attached     7/20/2017
The Single Best Hep C Drug Stock to Buy in 2017—Hint, It's Not Gilead (GILD)     6/12/2017
Why the Government Should Pay $156 Billion to Own Gilead (GILD)     1/18/2017
Gilead (GILD) CEO Remorseful Over Sovaldi's $1,000 Per Pill Price Tag     12/9/2016
Gilead (GILD) Drops Another Bombshell, Will Shift R&D Cash Away From Hep C     11/7/2016
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it     11/2/2016
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes?     10/18/2016
Achillion (ACHN), Johnson & Johnson (JNJ)'s Hep C Candidate Scores a 100% Cure Rate in Phase IIa Trial     9/9/2016
FDA Green Lights AbbVie (ABBV) Once-Daily Viekira XR for Hepatitis C     7/26/2016
Gilead (GILD)'s Strategy for New Hep C Drug Epclusa     7/7/2016
Regulus (RGLS) Shares Crumble As FDA Puts Hep C Treatment on Hold     6/28/2016
Gilead (GILD)'s Plan to Dominate the Hepatitis C Market     6/27/2016
Two Upstarts that Could Dislodge Gilead (GILD)'s Hold on the Hepatitis C Market     6/22/2016

News from Around the Web
AbbVie (ABBV)’s New, Cheaper Hepatitis C Drug Could Launch The Drug World’s Own Hunger Games     8/7/2017
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs     7/19/2017
3 Numbers That Make Gilead (GILD) Look Cheaper Than It Really Is     3/17/2017
New Report Questions the Safety of Gilead (GILD)'s Pricey Hep C Drugs     1/26/2017
Gilead (GILD)'s Hep C Med the Most Costly for Medicare, Medicaid in 2015     11/15/2016
University of Pennsylvania Study Looks To Speed Transplants With Hepatitis C-Infected Kidneys     10/28/2016
The Lab Breakthrough And The Two Men Behind Today’s Pricey Hepatitis C Cures     9/13/2016
Vietnam Vets Blame "Jet Guns" For Their Hepatitis C     2/15/2016
One-Step Test For Hepatitis C Virus Infection Developed, University of California, Irvine Health Researchers Reveal     11/16/2015
Gilead (GILD) Beats AbbVie (ABBV) Again     9/22/2015
China Rejects Patent Linked To Gilead (GILD) Hepatitis C Drug     6/22/2015
Gilead (GILD) Holds Cash Overseas to Save Billions on Taxes     2/27/2015
Gilead Sciences, Inc. (GILD)'s $1,000-A-Pill Hepatitis C Drug May Make Financial Sense For Prisons     10/21/2014
Gilead Sciences, Inc. (GILD) Looks To Erase Bristol-Myers Squibb Company (BMY)'s Early Hep C Lead     9/30/2014
What Happened At BioPharm America 2014?     9/24/2014

Press Releases
China Food And Drug Administration Approves Gilead (GILD)’s Sovaldi (Sofosbuvir) For Treatment Of Chronic Hepatitis C Virus Infection     9/25/2017
Medivir (MVRBF) Announces Janssen To Discontinue Development Of JNJ-4178 For Hepatitis C     9/11/2017
Enanta Pharmaceuticals, Inc. Announces U.S. FDA Approval Of AbbVie (ABBV)’s MAVYRET (Glecaprevir/Pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6) In As Little As 8 Weeks     8/4/2017
Gilead (GILD) Release: U.S. FDA Approves Expanded Labeling For Epclusa (Sofosbuvir/Velpatasvir) For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV     8/2/2017
European Commission (EC) Grants Marketing Authorization For Gilead (GILD)’s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Genotypes Of Chronic Hepatitis C     7/28/2017
European Commission (EC) Grants AbbVie (ABBV)'s MAVIRET (Glecaprevir/Pibrentasvir) Marketing Authorization For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)     7/28/2017
Mylan (MYL) Launches MyHep All In India     7/27/2017
Mylan (MYL) Receives WHO Prequalification for Generic Sovaldi     7/26/2017
Enanta Pharmaceuticals, Inc. Announces That AbbVie (ABBV) Receives CHMP Positive Opinion For MAVIRET (Glecaprevir/Pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)     6/23/2017
European CHMP Adopts Positive Opinion For Gilead (GILD)’s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Chronic Hepatitis C Genotypes     6/23/2017
AbbVie (ABBV) Receives CHMP Positive Opinion For MAVIRET (Glecaprevir/Pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)     6/23/2017
CDC Release: New Hepatitis C Infections Nearly Tripled Over Five Years     5/15/2017
Digestive Disease Week Release: Study Identifies Genetic Markers That Predict Which Patients With Hepatitis C And Cirrhosis Will Improve With Treatment     5/9/2017
Merck & Co. (MRK) Announces New Phase II Data On Investigational Triple Combination Therapy MK-3682B For Chronic Hepatitis C     4/24/2017
Gilead (GILD) Announces Scientific Presentations Demonstrating Efficacy Of Harvoni (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection     4/24/2017